Pre-Surgical Trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: A New York Cancer Consortium Trial

INTRODUCTION: The PI3K/AKT/mTOR pathway is an oncogenic driver in breast cancer (BC). In this multi-center, pre-surgical study, we evaluated the tissue effects of the AKT inhibitor MK-2206 in women with stage I–III BC. MATERIALS AND METHODS: Two doses of weekly oral MK2206 were administered at days...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Oncol
Main Authors: Kalinsky, Kevin, Sparano, Joseph A, Zhong, Xiaobo, Andreopoulou, Eleni, Taback, Bret, Wiechmann, Lisa, Feldman, Sheldon M, Ananthakrishnan, Preya, Ahmad, Aqeel, Cremers, Serge, Sireci, Anthony N, Cross, Justin R, Marks, Douglas K, Mundi, Prabhjot, Connolly, Eileen, Crew, Katherine D, Maurer, Matthew A, Hibshoosh, Hanina, Lee, Shing, Hershman, Dawn L
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6222014/
https://ncbi.nlm.nih.gov/pubmed/29736694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12094-018-1888-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados